Buy & Sell Philip Morris International Inc. (PM) – Philip Morris International Inc. Price Today
Aura AI Summary
Key Stats
- $293.99BMarket Cap
- Consumer StaplesSector
- -19.26%3M Drawdown
- $340.49BEnterprise Value
- 3.12%Dividend Yield
- 4% Buy | 96% SellTrading Activity
- 79 daysTypical Hold Time
Philip Morris International Inc. (PM) is currently valued at a market capitalization of $293.99B, with an enterprise value of $340.49B. Over the past 52 weeks, Philip Morris International Inc. has traded between a low of $144.33 and a high of $191.86, highlighting its annual price range. Over the past three months, Philip Morris International Inc. has recorded a drawdown of -19.26%, reflecting recent price volatility. Philip Morris International Inc. offers a dividend yield of 3.12%, with the most recent dividend of $1.47 paid on 19 Mar 26. On average, investors hold Philip Morris International Inc. for approximately 79 days, indicating typical investor behavior on the platform.
About Philip Morris International Inc.
Philip Morris International is an international tobacco company with a product portfolio primarily consisting of cigarettes and reduced-risk products, including heat-not-burn, vapor and oral nicotine products, which are sold in markets outside the United States. The company diversified away from nicotine products with the acquisition of Vectura, a provider of innovative inhaled drug delivery solutions, in 2021.
Most Recent News
BlackSky to present at three key investor conferences in May and June 2026
BlackSky Technology Inc. announced its participation in three upcoming investor conferences: the Jefferies Virtual Space Summit on May 26, the 23rd Annual Craig-Hallum Institutional Investor Conference on May 28, and the Morgan Stanley National Secur...

LiquidStack launches GigaModular™ liquid cooling platform with 14 MW capacity for AI data centers
LiquidStack, a Trane Technologies company, has commercially launched its GigaModular™ CDU platform designed for high-density AI data centers. The platform offers flexible, scalable liquid cooling capacity up to 14 MW, enabling operators to expand coo...

Inventiva to present at 2026 Jefferies Global Healthcare Conference in June
Inventiva, a biopharmaceutical company developing oral therapy for metabolic dysfunction-associated steatohepatitis (MASH), announced its CEO Andrew Obenshain will present at the 2026 Jefferies Global Healthcare Conference in New York on June 3. The ...
